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ABSTRACT
Introduction In one- third of all abdominal aortic aneurysms 
(AAAs), the aneurysm neck is short (juxtarenal) or shows 
other adverse anatomical features rendering operations more 
complex, hazardous and expensive. Surgical options include 
open surgical repair and endovascular aneurysm repair (EVAR) 
techniques including fenestrated EVAR, EVAR with adjuncts 
(chimneys/endoanchors) and off- label standard EVAR. The 
aim of the UK COMPlex AneurySm Study (UK- COMPASS) is 
to answer the research question identified by the National 
Institute for Health Research Health Technology Assessment 
(NIHR HTA) Programme: ‘What is the clinical and cost- 
effectiveness of strategies for the management of juxtarenal 
AAA, including fenestrated endovascular repair?’
Methods and analysis UK- COMPASS is a cohort study 
comparing clinical and cost- effectiveness of different 
strategies used to manage complex AAAs with stratification of 
physiological fitness and anatomical complexity, with statistical 
correction for baseline risk and indication biases. There are 
two data streams. First, a stream of routinely collected data 
from Hospital Episode Statistics and National Vascular Registry 
(NVR). Preoperative CT scans of all patients who underwent 
elective AAA repair in England between 1 November 2017 
and 31 October 2019 are subjected to Corelab analysis to 
accurately identify and include every complex aneurysm 
treated. Second, a site- reported data stream regarding quality 
of life and treatment costs from prospectively recruited patients 
across England. Site recruitment also includes patients with 
complex aneurysms larger than 55 mm diameter in whom 
an operation is deferred (medical management). The primary 
outcome measure is perioperative all- cause mortality. Follow- 
up will be to a median of 5 years.
Ethics and dissemination The study has received full 
regulatory approvals from a Research Ethics Committee, 
the Confidentiality Advisory Group and the Health Research 
Authority. Data sharing agreements are in place with 
National Health Service Digital and the NVR. Dissemination 
will be via NIHR HTA reporting, peer- reviewed journals and 
conferences.
Trial registration number ISRCTN85731188.
Strengths and limitations of this study
 ► UK COMPlex AneurySm Study will include all pa-
tients undergoing repair of a complex abdominal 
aortic aneurysm (AAA) in England over a 24- month 
period in a comparative effectiveness analysis of 
high external validity.
 ► This study will involve the largest Corelab analysis of 
CT aortograms ever conducted to identify complex 
aneurysms according to predefined objective crite-
ria pertaining to aneurysm neck anatomy.
 ► This study will capture every treatment method used 
to repair complex aneurysms.
 ► This study will incorporate methods of accounting for 
baseline risk and indication biases arising from phys-
iological status and anatomical complexity, which will 
improve internal validity of comparative effectiveness 
analyses.
 ► The main limitation of the study design is a lack of ran-
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INTRODUCTION
Approximately 4000 individuals undergo elective repair 
of an abdominal aortic aneurysm (AAA) each year in the 
UK1 with the intention of preventing premature death 
from aneurysm rupture. The two distinct repair methods 
used, open surgical repair (OSR) and endovascular aneu-
rysm repair (EVAR), each have unique advantages and 
disadvantages. EVAR is safer within the perioperative 
period, but less durable in the years to follow compared 
with OSR. Treatment costs also differ between the two 
methods.
The complexity of aneurysm repair depends mainly on 
anatomical detail relating to the segment of undilated 
aorta between renal arteries and the aneurysm, referred 
to as the aneurysm ‘neck’. Ideal aneurysm neck has 
normal diameter in cross- section which is uniform along 
its length with little angulation, thrombus or calcification. 
Infrarenal aneurysms with at least 10–15 mm length of 
ideal aneurysm neck are amenable to OSR with aortic 
occlusion clamp below the renal arteries. Such anatomy 
also allows standard EVAR within ‘Instructions for Use’ 
(IFU) defined by manufacturers of stent- grafts implanted 
during EVAR. Some 40%–60% of aneurysms fall within 
this category2–4 and there is a wealth of comparative 
effectiveness evidence relating to such patients.5 6 The 
remainder, whose aneurysm neck is too short (commonly 
called ‘juxtarenal’) or otherwise unsuitable for standard 
EVAR within IFU (on- label device use), are pragmatically 
referred to as having a ‘complex aneurysm’.
OSR of complex aneurysms involves aortic occlusion 
clamps at a variety of levels; below the renal arteries (infra-
renal), below the superior mesenteric artery (suprarenal) 
or above the coeliac artery (supravisceral or supracoeliac) 
with increasing levels of physiological burden and tech-
nical difficulty as the clamp level moves higher. Complex 
aneurysms also call for advanced EVAR techniques such 
as fenestrated EVAR (FEVAR), and EVAR with adjuncts 
(including chimneys and endoanchors),7 all of which 
are more complex than standard EVAR. Standard EVAR 
outside IFU (off- label standard EVAR) is also used in 
routine clinical practice to treat complex aneurysms.
Repair of complex aneurysms by any technique is asso-
ciated with greater risk than repair of standard aneu-
rysms. Therefore, in patients with aneurysms larger than 
the conventional treatment threshold of 55 mm diameter 
and poor physiological status, a shared decision may be 
made to defer operation until the risk versus benefit turns 
favourable towards intervention. Such ‘medical manage-
ment’ of complex aneurysms with continued surveil-
lance beyond the 55 mm size threshold has never been 
compared with immediate operation.
Existing evidence for different methods of repair of 
complex aortic aneurysms is largely in the form of case 
series. Most published analyses are limited by selection 
and indication biases. The practice of offering OSR to 
physiologically fitter patients and reserving EVAR tech-
niques for the less fit patients is seldom accounted for 
in analyses comparing outcomes.8–10 Furthermore, in 
most analyses, patients are grouped by the operation 
techniques used rather than the detail of the anatomy 
being treated. A lack of precise and objective informa-
tion regarding aneurysm neck anatomy, pooling of short- 
neck aneurysms with aneurysms without a neck as well 
as aneurysms of the visceral aortic segment and thora-
coabdominal aortic aneurysms seriously limits the value 
of most published evidence.11–14 These sources of bias, 
confounding and heterogeneity, have been consistently 
recognised as weaknesses in the evidence base by authors 
of systematic reviews.15 16
There is therefore a pressing need to generate compar-
ative effectiveness evidence in this area with adequate 
internal and external validity. Expert opinion sought by 
the study funder, as well as an independently conducted 
workshop revealed that in the UK, a randomised 
controlled trial comparing OSR against FEVAR (the two 
principal repair methods) would not be feasible due 
mainly to a lack of sufficient equipoise. Additionally, such 
a trial would neglect other methods of complex aneurysm 
repair that are widely used, including off- label EVAR and 
EVAR with adjuncts (such as endoanchors).
Endovascular treatments are associated with greater 
cost than OSR due to the cumulative costs of the stent- 
grafts, ancillary devices, postoperative surveillance and 
re- intervention. National Health Service (NHS) clinical 
service commissioners have noted an increasing demand 
for FEVAR in the absence of evidence regarding clinical 
effectiveness identifying which patients would benefit 
from this procedure and whether the substantial cost 
associated with the technique is an appropriate use of 
NHS resources. Prohibitive cost and lack of experience 
with FEVAR in many arterial centres have concomitantly 
led to a substantial use of off- label standard EVAR in 
complex neck anatomy, an intervention that is known 
to have poorer long- term results compared with on- label 
EVAR.17 The National Institute for Health Research 
Health Technology Assessment (NIHR HTA) Programme 
has commissioned this comparative research study in 
order to resolve this NHS decision problem.
The primary aim of UK COMPlex AneurySm Study 
(UK- COMPASS) is to answer the research question iden-
tified by the NIHR HTA Programme: ‘What is the clinical 
and cost- effectiveness of strategies for the management 
of juxtarenal AAA, including fenestrated endovascular 




UK- COMPASS is an empirical cohort study comparing the 
clinical and cost- effectiveness of different management 
strategies used to repair complex aneurysms, incorpo-
rating statistical methods of correcting for confounding 
by physiological risk and anatomical complexity.
The study incorporates aspects which have been 
referred to by NIHR as ‘efficient study design’, where a 
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substantial proportion of data required for the analysis is 
retrieved from routinely collected sources. This reduces 
the cost of conducting research, facilitates inclusion of a 
large number of patients within a short time frame and 
reflects ‘real- world’ practice. The study has two streams of 
data collection:
Routinely collected data
This stream pertains to patients who have undergone 
repair of a complex aneurysm in England, over a 2- year 
period between 1 November 2017 and 31 October 2019. 
Duration of inclusion period was estimated to be 2 years 
commencing as soon as regulatory approvals are in place, 
anticipating at least 30% of aneurysms to fulfil inclusion 
criteria in order to provide adequate statistical precision. 
Health data, demographic data and healthcare resource 
use data relating to operated patients will be retrieved 
from Hospital Episode Statistics (HES) datasets (NHS 
Digital), the National Vascular Registry (NVR), and the 
NHS Picture Archiving and Communication System 
(PACS). Median follow- up will be 5 years, until 31 October 
2023.
The NVR is run by the Clinical Effectiveness Unit of 
the Royal College of Surgeons of England as a national 
clinical audit. Audit of NVR data revealed 95% case 
ascertainment and data completeness between 85.5% 
and 100% depending on the data point, with a median 
completeness of 93.3%. Data capture system incorporates 
a number of validations ensuring high level of accuracy.1 
The NVR includes a wide range of data relevant to this 
study, including demographics, comorbidity, preoper-
ative assessment, intraoperative detail, postoperative 
complications, duration of hospital stay and critical care 
use for all types of AAA repair.
HES is a data warehouse containing details of all 
admissions, outpatient appointments, investigations and 
emergency department attendances at NHS hospitals 
in England. These data are collected during a patient’s 
time at hospital and are designed to enable administra-
tion as well as medical research. In addition to health and 
resource use data during the primary admission for aneu-
rysm repair, follow- up data will be collected for 5 years 
after the operation to identify late complications, treat-
ment of complications and re- interventions. Survival data 
are retrieved via Office for National Statistics data linked 
to HES. The quality of HES data is recognised to be 
adequate for research and is regularly used for research 
purposes.18
Site-reported data
 ► Quality of life (QoL) data prospectively reported by 
consenting patients (both operated and medically 
managed) from participating arterial centres in 
England will supplement the routinely collected data. 
Recruitment will be undertaken between 1 November 
2017 and 31 December 2022, with follow- up until 31 
December 2023.
 ► Baseline clinical data: participating centres will report 
baseline health and demographic data for patients 
recruited to the QoL aspect of the study.
Primary outcome measures are perioperative mortality, 
late all- cause mortality and late aneurysm- related 
mortality.
Secondary outcome measures are perioperative compli-
cation rates (including organ system complications, 
infections and complications specific to stent- grafts), 
perioperative secondary interventions, length of stay, 
intensive care usage, late complication rates (including 
complications specific to stent- grafts, renal failure/
dialysis, aneurysm complications, infection, incisional 
hernia), late secondary intervention and health economic 
measures including incremental cost- effectiveness ratio 
in terms of cost per incremental gain in quality- adjusted 
life years.
All primary and secondary outcome measures except 
the health economic measures will be derived solely from 
the routinely collected data sources (HES, NVR and 
imaging). The health economic outcomes will be derived 
from a combination of routinely collected data sources 
(HES) and site- reported data sources (QoL collection).
Table 1 The UK- COMPASS objectives
Objective 1 To compare different treatment strategies for their perioperative mortality and morbidity, corrected for 
confounding physiological and anatomical characteristics, in order to account for baseline risk and indication 
biases.
Objective 2 To identify whether particular physiological and/or anatomical baseline characteristics are associated with 
better clinical outcomes or better health economic efficiency using one or other treatment strategies.
Objective 3 To compare different treatment strategies in terms of overall survival and in terms of treatment failure in the 
long- term follow- up (stent- graft- related complications, secondary interventions, aneurysm- related mortality).
Objective 4 To perform cost- effectiveness analyses from NHS and personal social care perspective to establish incremental 
cost- effectiveness ratios, comparing different treatment strategies in terms of cost per incremental gain in and 
quality- adjusted life years.
Objective 5 To establish the clinical and cost utility of FEVAR and alternatives, in patients who are considered 
physiologically unfit for OSR, and to compare these against medical management.
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All interventions that have been used in the study popu-
lation will be compared as numbers allow. We anticipate 
methods of repair to include open surgery (OSR) with a 
variety of clamp levels (infrarenal, suprarenal or supravis-
ceral), FEVAR, off- label use of standard EVAR and EVAR 
with adjuncts (including chimneys and endoanchors).
METHODS
Routinely collected data
The study population of complex aneurysms for the 
routinely collected data stream will be identified through 
anonymised Corelab analysis of preoperative CT scans; 
a Corelab refers to a combination of infrastructure and 
methodology of image analysis according to predeter-
mined reporting standards and definitions. Corelab 
CT analysis will be undertaken for all AAAs repaired 
in England between 1 November 2017 and 31 October 
2019. These patients and details regarding their preop-
erative CT scans will be identified from the HES dataset 
and Diagnostic Imaging Dataset of NHS Digital. This will 
permit retrieval of CT scans from the provider site to the 
Corelab based at the Royal Liverpool University Hospital 
using the Internet Exchange Portal and PACS.
The CT scans will be analysed in the Corelab using 
a prespecified protocol that was devised using a clin-
ical consensus exercise conducted with experts from 
throughout the UK in December 2019. The Corelab 
protocol is provided in full in the online supplemental 
file and includes information on anatomical defini-
tions, in- depth information regarding the measurement 
process, as well as the results of a validation exercise. The 
anatomical CT- based inclusion and exclusion criteria for 
the routinely collected data stream are summarised in 
table 2.
It is anticipated that approximately 8000 preopera-
tive CT scans will be analysed in the Corelab and that of 
these, approximately 3000 patients will meet the anatom-
ical inclusion criteria for a complex neck. These patients 
are included in the analysis without further selection or 
randomisation. Pseudonymised baseline and postopera-
tive follow- up data (up to 5 years) will be provided for 
this population of patients with complex necks, using 
datasets from NHS Digital and the NVR. Additionally, 
intraoperative images and postoperative surveillance for 
the patients treated by endovascular techniques will be 
retrieved to the study Corelab.
Site-reported data
All arterial vascular centres in England are eligible to 
participate as recruitment centres for the site- reported 
data stream. Recruitment will be undertaken between 1 
November 2017 and 31 December 2022, with follow- up 
QoL data collected until 31 December 2023.
Patients will be prospectively identified at recruiting 
sites and approached for QoL follow- up using Good Clin-
ical Practice- compliant processes. The anatomical inclu-
sion criteria used to identify the patients mirror those 
of routinely collected data (see table 2). Patients will be 
eligible for contribution to QoL data collection if they are 
due to have a complex aneurysm managed with open or 
endovascular surgery, as well as cases that have reached 
55 mm in maximal diameter and are selected to remain 
on extended surveillance (‘medical management’) with 
decision for treatment made at a later date once the aneu-
rysm has reached a larger threshold diameter.
In addition to the anatomical exclusion criteria listed 
in table 2, cases using surgeon- modified stent- grafts and 
cases in which patients are outright turned down for 
surgery due to comorbidity or patient choice (‘opera-
tion declined’) will be ineligible for recruitment to QoL 
follow- up.
Both generic (EuroQuol- 5D- 5L, EQ- 5D- 5L19) and 
aneurysm- specific (Aneurysm- Dependent Quality of Life, 
Aneurysm DQoL20) QoL questionnaires will be used to 
collect data according to prespecified time points for 
both operated and medically managed patients as shown 
in table 3. The data will be collected in the form of written 
completed questionnaires or telephone interviews, in 
accordance with patient preference with raw data entered 
Table 2 CT- based anatomical inclusion and exclusion criteria for the routinely collected data stream
Inclusion criteria Exclusion criteria
Aneurysm diameter ≥55 mm AND neck length <10 mm Ruptured aneurysm
Aneurysm diameter ≥55 mm AND neck length ≥10 mm AND the presence of ≥1 of 
the following adverse neck features:
 ► Beta (β) angle >60°
 ► Conicality (>10% change in diameter along 15 mm length of neck)
 ► Thrombus lining >1/3 circumference of the neck OR filling 1/3 the surface area 
of the neck along a 3 mm length of neck
 ► Calcium load in the wall of the neck affecting >1/3 circumference of the neck 
along a 3 mm length of neck
 ► Non- straight neck, defined by the presence of intraneck angulation of >60° 
with a juxtarenal neck length of <15 mm
 ► Alpha (α) angle >45°
Subthreshold aneurysm (<55 m)
Thoracic aortic aneurysm
Thoracoabdominal aortic aneurysm
Visceral aortic aneurysm (where aorta at 
level of SMA is ≥30 mm)
SMA, superior mesenteric artery.
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and stored onto secure database by trained staff at the 
Liverpool Clinical Trials Centre. Change in overall QoL 
between baseline and subsequent intervals will be anal-
ysed for statistical significance. This information will also 
inform health economic analyses. A patient diary will also 
be completed by patients annually to provide data on 
health resource use following their aneurysm treatment.
Recruiting sites will also be asked to conduct a micro-
costing exercise in order to assess variations in endovas-
cular consumables and local practice. A detailed cost 
profile will be obtained for at least 10 patients treated 
by each treatment modality: OSR, FEVAR and EVAR 
(±adjuncts). A proforma for microcosting data collection 
is included in the online supplemental file.
Sample size calculations
Perioperative mortality
The primary outcome measure is perioperative death. The 
primary efficacy parameter is the OR comparing FEVAR 
with both open repair and off- label EVAR. For OSR, 
conservative estimate of 8% perioperative death might 
be expected, and a reduction to 4% could be consid-
ered clinically relevant, which is equivalent to an OR of 
0.48 (based on NVR 2015 report21 and GLOBALSTAR 
registry22). This effect is slightly larger than that noted in 
randomised controlled trials of standard infrarenal aneu-
rysm repair.5 A Bonferroni adjusted two- sided alpha level 
of 0.025 is used. Based on these assumptions, collecting 
data on 2000 patients will ensure a power in excess of 
80% if the allocation between treatments is relatively 
equal and should be preserved above 70% even if one 
treatment strategy is used twice as much as the other two.
Stratified comparative analysis for perioperative mortality and 
identification of risk factors
Based on the best available estimates, it is anticipated 
that 120 events (perioperative deaths) will be available 
if 2000 patients are included in the study. The aim is 
to identify anatomical/physiological characteristics for 
which there is a differential effect on patient outcome 
depending on the treatment strategy employed. We plan 
to use multivariable models which include propensity 
scores as continuous covariates, adjusted for appropriate 
confounding variables and including interaction effects 
with treatment effect. Using the statistical rule of thumb 
of 10 events per variable, approximately 12 variables can 
be included in any single model. If, for example, a two- 
level factor is to be investigated, main effects and inter-
action effects and a covariate of propensity scores will 
account for six variables, allowing for a further inclusion 
of other confounding variables as required.
Long-term survival; all-cause mortality
Estimated survival rates at 1, 2 and 4 years are 90%, 80% 
and 70%, respectively. All patients will have a median of 
5- year follow- up after entering the study. It is approxi-
mated that 2000 patients should then contribute approx-
imately 550 events (all- cause mortality after 30 days/
discharge). As the study is not designed to identify a 
difference in long- term overall survival, no power calcula-
tion is provided to detect some minimum clinically rele-
vant difference. Instead, assuming the difference between 
two treatment arms to be measured using a log HR, it is 
estimated that from 550 events, an SE of approximately 
0.085 will be observed. This translates to a 95% CI of 
length of approximately 0.34. Here, an HR smaller than 
0.71 or larger than 1.40 will be shown to be significant at 
a 5% level.
Quality of life
We will obtain QoL data from a representative sample 
of patients undergoing AAA surgery during the study 
period. This will equate to 800 patients. We expect a 50% 
loss to follow- up, through non- compliance and natural 
attrition from death during the follow- up period. We plan 
to obtain QoL from 300 medically managed patients. 
Three hundred patients will give a 95% CI of maximum 
width 12.5 for the difference in mean EQ- 5D- 5L Visual 
Analogue Scale (EQ- VAS) values between baseline and 
later time points based on an SD equal to 20. The SD was 
calculated after an evaluation of EQ- VAS scores across a 
wide range of trials.







postop 1 year postop
Annually up to 5 years 
postop
Operated patients
  EQ- 5D- 5L ✓ ✓   ✓ ✓ ✓
  Aneurysm- DQoL ✓   ✓   ✓ ✓
  Health diary         ✓ ✓
Medically managed patients (time points relative to recruitment/baseline questionnaire date and not the date of an operation)
  EQ- 5D- 5L ✓     ✓ ✓ ✓
  Aneurysm- DQoL ✓       ✓ ✓
  Health diary         ✓ ✓
Aneurysm- DQoL, Aneurysm- Dependent Quality of Life; EQ- 5D- 5L, EuroQuol- 5 Dimension- 5 Level.
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Data analysis plan
Analyses will be carried out on an intention- to- treat basis, 
retaining all patients in the surgery group to which they 
are assigned irrespective of any procedural issues. The 
intervention groups will be OSR, FEVAR, EVAR±ad-
juncts (including chimneys and endoanchors). The exact 
treatment received will be determined by triangulation 
of NVR data and HES data for OSR. Patients receiving 
endovascular treatment will be identified from NVR data 
and HES data, and exact technical details of each proce-
dure (including the use of adjuncts) will be determined 
through analysis of procedural images in the Corelab.
As an analysis of observational cohort data, all attempts 
to present a measure of efficacy free from confounding 
bias will be undertaken. Patients will be stratified by infra-
renal neck length for analysis into three groups: 0- 4 mm 
(juxtarenal), 5–9 mm (juxtarenal) and ≥10 mm neck 
length (not juxtarenal but complex based on device- 
specific IFU criteria). This will serve to limit anatomical 
heterogeneity and bias within comparisons. Additionally, 
patients will be stratified by physiological risk. The British 
Aneurysm Repair Score23 will be used (11 clinical param-
eters available from NVR data) to divide each comparison 
group into those that are high risk (the highest risk quar-
tile) and the remainder as standard risk.
Statistical analyses of the primary outcome shall follow 
the principle of propensity score analysis. Propensity 
score estimation is chosen for the analysis of the primary 
endpoint instead of multivariable regression techniques 
because it is considered the most appropriate means of 
accounting for selection bias at the low level of perioper-
ative death rates anticipated.24 Propensity scores estimate 
the probability of a patient being given each treatment 
strategy based on baseline clinical and demographic char-
acteristics. Patients can then be stratified based on their 
propensity to receive each treatment strategy and an esti-
mate of treatment effect is then obtained, which adjusts 
for potential selection bias in the data.
Models to estimate the propensity for each patient shall 
be generated using multivariable logistic modelling tech-
niques using as candidate covariates only variables that 
influence simultaneously the treatment assignment and 
the outcome variable. Covariates shall be retracted to 
demographic/clinical data available at the point of treat-
ment decision with the aim of producing a propensity 
model that satisfies the assumptions of conditional inde-
pendence. The final analysis shall be carried out using 
stratified logistic where the strata are defined by the quin-
tiles of the fitted propensity score values. Prior to anal-
yses, it shall be confirmed that each stratum contains at 
least 20 observed perioperative deaths. If not, the strata 
will be combined with an adjacent strata level.
The key efficacy parameter of interest will be an OR 
presented with a 97.5% CI. Results will be presented as 
a forest plot with the OR within each stratum presented 
along with the overall effect.
Reports of HES data validation confirm high levels of 
completeness and accuracy. Therefore, missing data or 
inaccurate data are unlikely to be a significant problem. 
It is proposed that covariates with small amounts of 
missing data (≤10%) will be included on a complete case 
basis and covariates with a large amount of missing data 
(>10%) will be excluded from the analysis.
Sensitivity analyses are carried out to ensure the 
results are not sensitive to either the propensity model 
or the method of matching. With respect to the propen-
sity model, sensitivity analyses shall be carried out by 
removing each covariate included in calculating the 
propensity score and repeating the analysis of the primary 
endpoints. The results of all sensitivity analyses shall be 
presented in a forest plot along with the overall effect 
from the primary analysis.
It is recognised that recruitment for site- reported QoL 
data will occur either side of a cessation of elective services 
in the UK due to the COVID- 19 pandemic in 2020/2021. 
There may be differences in patient behaviour and clin-
ical practice before and after this period and we aim 
to investigate this further in the analysis phase. First, 
outcome data before and after the dates of interest will 
be compared. Second, clinical practice before and after 
the dates of interest will be compared using data from 
the NVR.
Health economic analysis
The UK- COMPASS will adapt the recent National Insti-
tute for Health and Care Excellence (NICE) health 
economic analysis model25 which will facilitate updates of 
NICE Clinical Guideline ‘Abdominal Aortic Aneurysm–
Diagnosis and Management (NG156)’.
Our aim is to inform NICE decision- making in a timely 
manner. The NICE health economic model has been 
developed from a UK NHS and Personal Social Services 
perspective, appraised by a NICE committee and scru-
tinised during consultation, and we see this fit to be 
adapted without developing a de novo model.
The purpose of the health economic analysis in this 
study is defined in the original objectives 4 and 5. The 
main outputs therefore will remain (a) estimation of 
incremental cost- effectiveness ratios comparing different 
treatment strategies in terms of life years and quality- 
adjusted life years gained, and (b) to identify whether 
particular level of physiological fitness (stratified into 
two groups) and/or anatomical baseline characteristics 
(stratified into three groups) are associated with better 
health economic efficiency using one or other treatment 
strategies.
At least 5- year follow- up is considered the essential 
minimum to capture attrition of treatment utility and 
accrual of treatment costs that occur from late failure/
secondary intervention and postoperative surveillance.
Patient and public involvement
The Liverpool Aneurysm Research patient and public 
involvement (PPI) group has been actively involved in the 
study. The study proposal was initially presented to the 
group on 2 November 2015 with subsequent follow- up.
 on D
ecem









pen: first published as 10.1136/bm






7Patel SR, et al. BMJ Open 2021;11:e054493. doi:10.1136/bmjopen-2021-054493
Open access
Our PPI representatives strongly welcomed the 
proposed research and supported the team throughout 
the process of grant application and subsequently in the 
oversight of the study. The PPI group considered the 
dilemmas arising out of access to routinely collected data 
for this research project, including NHS number and 
date of birth, without explicit and specific consent from 
each patient. They scrutinised and approved the data 
management plan.
With appropriate safeguards in place, they felt that 
research using routinely collected data in the manner 
proposed here may have some advantages, by potentially 
reducing anxiety associated with being approached to 
participate in a prospective clinical study. They have also 
pointed out the benefits of data collected independent 
of physician or patient preference for a research study, 
thereby reducing bias. They welcomed the benefits of 
improved efficiency and improved generalisability of 
results across wider NHS.
The PPI group has helped us review the lay summary 
and has also reviewed the grant application at all stages. 
Once the study has commenced, the PPI group has been 
expended and annual meetings are expected to monitor 
progress. The Trial Steering Committee has one PPI 
member as an independent member. The PPI group is 
also expected to help with dissemination of research find-
ings by reviewing patient education material as well as 
supporting commissioning decisions as appropriate.
ETHICS AND DISSEMINATION
The study protocol, informed consent form, patient infor-
mation sheet and all other patient- facing study documen-
tation have received the favourable opinion of the North 
West–Preston Research Ethics Committee and Health 
Research Authority (HRA) approval.
Access to patient data in NHS Digital datasets, the 
NVR dataset as well as to imaging, without the need for 
patient consent, has been granted by the Confidentiality 
Advisory Group (CAG); CAG is an independent body 
which provides expert advice to the HRA and the Secre-
tary of State for Health on whether applications to access 
confidential patient or service user information without 
consent should or should not be approved.
The study is managed by the Liverpool Clinical Trials 
Centre. The sponsor for the study is Liverpool University 
Hospitals NHS Foundation Trust.
Dissemination plan
The results of this study will be written up and published 
as an official report for the NIHR HTA. It will also be 
published in a peer- reviewed journal and presented at 
international conferences.
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